Leaning on BD to revive weak pipeline, Lundbeck plans to cut up to 160 jobs in R&D restructuring
During Lundbeck’s earnings call in mid-May, Johan Luthman, the EVP of R&D, was asked a pointed question hinting at the multiple setbacks his beleaguered group has faced:
Johan, now you’ve been at Lundbeck for a year, so are you satisfied with development that you have seen particularly on the internal development of projects? Do you think that you are responsible for a pipeline which can live up to the aspiration of creating a sustainable growth company?
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.